ArticleFrontiers in oncology2020
Performance Evaluation of
Article in Frontiers in oncology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 1 synthesis or guideline pooled it, 27 citations in OpenAlex.
- Clinical value of combinedOncology reviews · 2026Pooled it
- Biomarker Detection of Lung Cancers Before Clinical Symptoms or the Use of Traditional Imaging Methods in the ITALUNG Trial.International journal of molecular sciences · 2026Trial
- Multimodal modeling based on DNA methylation analysis in bronchoalveolar lavage fluid for early lung cancer detection.Scientific reports · 2026Trial
- A Dual-Marker DNA Methylation Assay Enables High-Sensitivity Detection of Malignant Effusions Across Cancer Types.Cancers · 2026Article
- A review of deep learning-based multimodal data integration of lung cancer.Clinical and experimental medicine · 2026Review
- Transcript-Specific DNA Methylation Alterations of the RASSF1 Locus in Cancer Cells.Genes, chromosomes & cancer · 2026Article
- Small-scale external quality assessment of methylatedClinical chemistry and laboratory medicine · 2026Article
- Epigenetic profiling of circulating cell-free DNA for early detection and minimal residual disease assessment in lung cancer: a focus on DNA methylation.Frontiers in oncology · 2026Review
- Detection ofMolecular and clinical oncology · 2025Article
- Diagnostic efficacy and subgroup heterogeneity of SHOX2, RASSF1A, Septin9, and HOXA9 methylation in pleural effusion lymphoma.Clinical epigenetics · 2025Article
- Enhancing the precision of auxiliary diagnosis for lung cancer through use ofTranslational lung cancer research · 2025Article
- Epigenetic regulation of the tumor microenvironment in lung cancer: mechanism insights and therapeutic prospects.Frontiers in immunology · 2025Review
- Diagnostic and prognostic value of polygene methylation detection in ascites.Frontiers in genetics · 2025Article
- Association of the SHOX2 and RASSF1A methylation levels with the pathological evolution of early-stage lung adenocarcinoma.BMC cancer · 2024Article
- Evaluating the comprehensive diagnosis efficiency of lung cancer, including measurement of SHOX2 and RASSF1A gene methylation.BMC cancer · 2024Article
- Utility of SHOX2 and RASSF1A gene methylation detection on the residual cytology material from endobronchial ultrasound-guided transbronchial needle aspiration.CytoJournal · 2024Article
- Link between m6A modification and infiltration characterization of tumor microenvironment in lung adenocarcinoma.Experimental biology and medicine (Maywood, N.J.) · 2023Article
- A novel multimodal prediction model based on DNA methylation biomarkers and low-dose computed tomography images for identifying early-stage lung cancer.Chinese journal of cancer research = Chung-kuo yen cheng yen chiu · 2023Article
- Diagnostic performance of RASSF1A and SHOX2 methylation combined with EGFR mutations for differentiation between small pulmonary nodules.Journal of cancer research and clinical oncology · 2023Article
- miR-375 Combined with SHOX2 Methylation has Higher Diagnostic Efficacy for Non-Small-Cell Lung Cancer.Molecular biotechnology · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Emerging molecular diagnostic methods are more sensitive and objective, which can overcome the intrinsic failings of morphological diagnosis. Here, a RT-PCR-based
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.